Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Zeta Global Joins Forces With Snowflake to Spearhead Open Semantic Interchange to Establish a Universal Data Standard for AI-Powered Marketing
NEW YORK, May 16 -- Zeta Global, an American marketing technology company, issued the following news release on May 15, 2026:* * *
Zeta Global Joins Forces with Snowflake to Spearhead Open Semantic Interchange to Establish a Universal Data Standard for AI-Powered Marketing
Initiative brings together leading data, AI, and marketing platforms to eliminate the fragmented definitions that undermine enterprise AI and analytics
*
Zeta Global (NYSE: ZETA), the AI Marketing Cloud, today announced it is joining the Open Semantic Interchange (OSI), an open source initiative that creates a universal ... Show Full Article NEW YORK, May 16 -- Zeta Global, an American marketing technology company, issued the following news release on May 15, 2026: * * * Zeta Global Joins Forces with Snowflake to Spearhead Open Semantic Interchange to Establish a Universal Data Standard for AI-Powered Marketing Initiative brings together leading data, AI, and marketing platforms to eliminate the fragmented definitions that undermine enterprise AI and analytics * Zeta Global (NYSE: ZETA), the AI Marketing Cloud, today announced it is joining the Open Semantic Interchange (OSI), an open source initiative that creates a universalspecification for all companies to standardize their fragmented data definitions with an open, vendor-neutral semantic model specification. OSI aims to enhance interoperability across various tools and platforms, offering enterprises a vendor-neutral specification that provides consistent metrics and definitions across dashboards, notebooks, and machine learning models.
OSI is an open source initiative led by Snowflake, the AI Data Cloud company, and ecosystem partners across multiple domains and industries including business intelligence (BI), data governance, data engineering, AI, financial services, and manufacturing. Its goal is to create a common, vendor-agnostic specification that defines semantic metadata in a standard, open format. By facilitating seamless semantic metadata exchange, the initiative will accelerate the adoption of AI and BI tools to streamline operations and reduce complexity. This in turn allows organizations to unify their data definitions, leading to more comprehensive and accurate data analysis and data product sharing to fuel AI innovation.
"AI is only as effective as the data it can trust. Zeta processes trillions of consumer signals across the marketing ecosystem, and we see firsthand how fragmented definitions erode trust in analytics and AI," said Christian Monberg, Chief Technology Officer and Head of Product at Zeta Global. "That's why working with Snowflake through the Open Semantic Interchange is so important. By aligning on a common foundation for how business metrics are defined and shared, we can help customers unlock more consistent insights and better outcomes across their marketing and data ecosystems."
As a member of OSI, Zeta is helping to build a transparent and community-driven standard for semantic model sharing, ensuring that business metrics and definitions remain consistent and interoperable. For Zeta's enterprise customers, OSI adoption means their ZMP data and insights can interoperate seamlessly with the broader data and AI tools in their stack, reducing integration friction and accelerating time to value.
"Unlocking the full potential of data and AI requires a common foundation, and the Open Semantic Interchange is the critical step in building that bedrock," said Josh Klahr, Director of Analytics Product Management at Snowflake. "Our collaboration with partners like Zeta establishes a unified, vendor-neutral standard for semantic data, ensuring clarity and consistency across the entire ecosystem. This initiative is essential for simplifying data operations, fostering innovation, and preparing organizations to build the next generation of AI applications."
OSI is poised to revolutionize interoperability within the data and AI ecosystem by providing a transparent, community-driven standard. This collaborative effort simplifies data operations, unlocks new possibilities for innovation, and gives organizations the flexibility and efficiency they need to build a future-ready data infrastructure.
* * *
About Zeta Global
Zeta Global (NYSE: ZETA) is the AI Marketing Cloud that leverages advanced artificial intelligence (AI) and trillions of consumer signals to make it easier for marketers to acquire, grow, and retain customers more efficiently. Through the Zeta Marketing Platform (ZMP(R)), our vision is to make sophisticated marketing simple by unifying identity, intelligence, and omnichannel activation into a single platform - powered by one of the industry's largest proprietary databases and AI. Our enterprise customers across multiple verticals are empowered to personalize experiences with consumers at an individual level across every channel, delivering better results for marketing programs. Zeta was founded in 2007 by David A. Steinberg and John Sculley and is headquartered in New York City with offices around the world.
* * *
Forward-Looking Statements
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning our anticipated future financial performance, our market opportunities and our expectations regarding our business plan and strategies. These statements often include words such as "anticipate," "believe," "could," "estimates," "expect," "forecast," "guidance," "intend," "may," "outlook," "plan," "projects," "should," "suggests," "targets," "will," "would" and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results.
The forward-looking statements are subject to and involve risks, uncertainties and assumptions, and you should not place undue reliance on these forward-looking statements. These cautionary statements should not be construed by you to be exhaustive and the forward-looking statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
* * *
Original text: https://zetaglobal.com/news/zeta-global-joins-forces-with-snowflake-to-spearhead-open-semantic-interchange-to-establish-a-universal-data-standard-for-ai-powered-marketing/
[Category: BizComputer Technology]
Littelfuse Expands Its Shock Block Ground-Fault Circuit Interrupter Series With the SB4000
CHICAGO, Illinois, May 16 -- Littelfuse, a circuit protection manufacturer, issued the following news release:* * *
Littelfuse Expands Its Shock Block(R) Ground-Fault Circuit Interrupter (GFCI) Series with the SB4000
New compact GFCI device offers protection for systems with a maximum full load current up to 30A.
*
ROSEMONT, Ill -- Littelfuse, Inc. (NASDAQ: LFUS), a leader in developing smart solutions that enable safe and efficient electrical energy transfer, expands its Industrial Shock Block Series to help protect workers from electrical shock for loads up to 30A. The SB4000 is available ... Show Full Article CHICAGO, Illinois, May 16 -- Littelfuse, a circuit protection manufacturer, issued the following news release: * * * Littelfuse Expands Its Shock Block(R) Ground-Fault Circuit Interrupter (GFCI) Series with the SB4000 New compact GFCI device offers protection for systems with a maximum full load current up to 30A. * ROSEMONT, Ill -- Littelfuse, Inc. (NASDAQ: LFUS), a leader in developing smart solutions that enable safe and efficient electrical energy transfer, expands its Industrial Shock Block Series to help protect workers from electrical shock for loads up to 30A. The SB4000 is availablefor use in single-, split- and three-phase systems as well as 4-wire systems from 208 to 240V.
SB4000 models equipped with connections for a neutral wire have built-in grounded-neutral protection per the UL 943 standard. The standard enclosure is IP 69K/NEMA 4X and outdoor rated making it suitable for all industrial environments including high temperature washdown used in food production applications. The SB4000 is panel agnostic making it perfect for remodel and retrofit applications in commercial kitchens, HVAC, and residential pool & spa applications. It includes advanced harmonic filtering, an automatic self-test feature, and is compliant to the UL 1998 Software in Programmable Components standard.
"In industrial and OEM environments, where 30-amp circuits power critical equipment, GFCI protection isn't optional-it's essential, especially where moisture and heavy-duty equipment intersect," stated Tim Piemonte, Product Manager at Littelfuse. "The compact, cost-effective Shock Block SB4000 is a frontline defense against electrical hazards instantly disconnecting power in the event of a ground fault, and is a proactive step toward compliance, reliability and most importantly worker safety."
Other feature and benefits include:
- UL 943 inverse time detection circuit protects people and the probability of nuisance tripping
- Fixed 6 mA trip level meets UL 943 GFCI personnel protection requirements
- Streamlined design eliminates flying leads and offers flexible positioning for knockouts
- Conformally coated circuit boards protect against corrosion and moisture
- Quick installation and easy configuration save time and money
The UL Listed/* SB4000 Shock Block series is a Class A GFCI available in 208 - 240V allowing maintenance or retrofit projects to meet the National Electrical Code NEC 210.8 for a wide variety of single-, split-, three-phase and 4-wire (neutral supported) systems.
For more information visit: www.Littelfuse.com/SB4000.
* * *
*/ UL Listed Class A GFCI (UL943)
* * *
About Littelfuse
Littelfuse is a diversified, industrial technology manufacturing company empowering a sustainable, connected, and safer world. Across more than 20 countries, and with approximately 16,000 global associates, we partner with customers to design and deliver innovative, reliable solutions. Serving over 100,000 end customers, our products are found in a variety of industrial, transportation, and electronics end markets-everywhere, every day. Learn more at Littelfuse.com.
* * *
Original text here: https://www.littelfuse.com/company/news-and-events/in-the-news/newspages-articles/press-releases/2026/littelfuse-expands-its-shock-block-ground-fault-circuit-interrupter-gfci-series-with-the-sb4000
[Category: BizManufacturing]
LinkedIn: How AI Is Reshaping Entrepreneurship for Gen Z and Small Business Owners
SUNNYVALE, California, May 16 -- LinkedIn, a professional networking tool, issued the following news:* * *
How AI Is Reshaping Entrepreneurship for Gen Z and Small Business Owners
Artificial Intelligence (AI) is transforming entrepreneurship by lowering barriers like cost, connections, and expertise. As a result, 77% of founders say it's now accessible to start and grow a business regardless of background. Gen Z is driving this shift, with 73% managing multiple income streams and using AI to start and grow businesses. The result is a rise in flexible "portfolio careers," where networks, personal ... Show Full Article SUNNYVALE, California, May 16 -- LinkedIn, a professional networking tool, issued the following news: * * * How AI Is Reshaping Entrepreneurship for Gen Z and Small Business Owners Artificial Intelligence (AI) is transforming entrepreneurship by lowering barriers like cost, connections, and expertise. As a result, 77% of founders say it's now accessible to start and grow a business regardless of background. Gen Z is driving this shift, with 73% managing multiple income streams and using AI to start and grow businesses. The result is a rise in flexible "portfolio careers," where networks, personalbranding, and digital tools are key to success.
Key findings from LinkedIn's research:
- 77% of founders say entrepreneurship is accessible regardless of background
- 73% of Gen Z entrepreneurs have multiple income streams
- 69% of founders say entrepreneurship is more achievable than ever
- 75% of entrepreneurs say networks are critical to success
- 68% of Gen Z entrepreneurs say AI is important to their business
How are Gen Z entrepreneurs reshaping business?
New research from LinkedIn shows how the use of AI, shifting career priorities, and evolving definitions of success are reshaping how businesses are started and grown.
Gen Z is leading a shift toward more flexible ways of working, with nearly three-quarters (73%) of Gen Z entrepreneurs reporting multiple income streams, compared to 56% of Gen X. This highlights growth in "portfolio careers" designed to build resilience and create greater control over work and income.
How is AI making entrepreneurship more accessible?
AI and digital tools are making entrepreneurship more accessible, lowering traditional barriers such as cost, connections, and expertise. More than three-quarters (77%) of founders say entrepreneurship is accessible regardless of background, while 69% say it is more achievable today than ever before.
Younger entrepreneurs are driving this change, with more than two-thirds (68%) of Gen Z entrepreneurs reporting that AI and digital tools are important to their business, more than twice the rate of Baby Boomers (27%). Nearly one in five (18%) Gen Z entrepreneurs say AI made starting their business feel possible.
AI is also helping small business owners compete for talent: 57% of US entrepreneurs say that AI can help them compete with larger companies to find and attract better candidates.
Related: The AI Edge for Entrepreneurs
* * *
What makes Gen Z entrepreneurs different? ... Has multiple income streams ... AI is important to their business ... Comfortable taking big risks
Gen Z ... 73% ... 68% ... 29%
Gen X ... 56% ... 27% ... 10%
* * *
How are younger entrepreneurs redefining success?
While flexibility and financial independence remain key motivators across generations, younger entrepreneurs are redefining success. Gen Z is the most likely generation to define success in terms of financial wealth (56%), and is more willing to take risks to get there, nearly three times more likely than Baby Boomers (29% vs. 10%). This group is also more likely to experiment with testing new business ideas before committing (20%), compared to just 8% of Gen X.
Why are networks and personal branding more important than ever?
Building strong networks and personal brands is also critical to growth. Three-quarters (75%) of entrepreneurs say their professional network has been important to starting or growing their business. More than six in ten entrepreneurs also identify as content creators, highlighting the importance of personal branding and audience-building in today's business landscape.
Related: Small Business Marketing
How can LinkedIn tools help entrepreneurs start and grow their businesses?
- Tools to build your brand: Create a founder-led profile that tells your unique story with Premium Business. Add Dynamic Cover Images to stand out as well as your call to action, such as website link via Custom Button - making your profile an always-on business card. We're also starting to roll out Advice Sessions so you can offer paid sessions directly on your profile.
- Hire right the first time: With a new AI-powered chat experience in Hiring Pro, you can work with LinkedIn's hiring agent in plain language, helping you refine candidate criteria, share feedback, and save time so you can find the right person to grow your business.
- Streamline all your business needs: With Premium All-in-One, small business leaders can find customers, market their services, and hire talent - streamlining every step of business growth through a single, trusted platform. Early subscribers are seeing increased visibility on LinkedIn, including a 57% rise in followers and a 40% increase in profile views.
- Grow your company's visibility. With Premium Company Page, you can enhance your business's credibility and attract more prospects. Premium Company Pages get up to 7.5x more engagement and 5.8x more Page views. This includes [NEW] Competitor Analytics to help you benchmark your company's results against up to 9 other companies.
Related: Grow your business with LinkedIn
Find out more about the new products LinkedIn has rolled out to help founders and entrepreneurs grow their small business here.
To help entrepreneurs scale their business, build their brand and harness AI, LinkedIn is offering free courses through LinkedIn Learning, unlocked until the end of 2026:
- Scaling Your Small Business
- The AI Edge for Entrepreneurs
- Small Business Marketing
We're crowdsourcing the best advice for the next generation of founders. Add your voice to the mix using #SmallBizMonth, check out the latest trends in LinkedIn's Entrepreneur Special report and discover the tools to help you scale at LinkedIn.com/smallbusiness.
FAQs: Entrepreneurship, AI, and Gen Z
1. How is AI changing entrepreneurship?
AI is lowering traditional barriers such as cost, access to expertise, and networks, making it easier for more people to start and grow businesses. As a result, 77% of founders say entrepreneurship is now accessible regardless of background.
2. Why are more Gen Z entrepreneurs starting businesses?
Gen Z is embracing entrepreneurship as a flexible career path, with 73% running multiple income streams. They are more likely to use AI and digital tools to launch and scale ventures, helping them experiment with new ideas and build resilient, diversified careers.
3. What is a "portfolio career" in entrepreneurship?
A portfolio career refers to building multiple income streams instead of relying on a single job or business. This approach is growing among younger entrepreneurs, allowing them to diversify income, reduce risk, and maintain greater control over their work and financial outcomes.
4. Is entrepreneurship more accessible today than before?
Yes, advances in AI and digital tools are making entrepreneurship more achievable. Nearly 69% of founders say it's more attainable than ever, as technology reduces the need for large upfront investment or traditional connections. LinkedIn is supporting this shift with AI-powered tools, such as its Hiring Assistant in Hiring Pro, which helps small business owners refine candidate searches and hire more efficiently.
5. What role do networks and personal branding play in entrepreneurship?
Networks and visibility are critical, with 75% of entrepreneurs saying their professional network helped them start or grow their business. Many are also building personal brands and creating content to attract customers, partners, and talent. LinkedIn tools such as Premium Business, Custom Button, and Premium Company Pages help entrepreneurs showcase their expertise, grow audiences, and drive engagement.
* * *
Original text: https://news.linkedin.com/2026/How-AI-Is-Reshaping-Entrepreneurship-for-Gen_Z-and-Small-Business-Owners
[Category: BizMedia]
Gartner Predicts by 2027, 50% of Enterprises Without a People Centric AI Strategy Will Lose Their Top AI Talent
STAMFORD, Connecticut, May 16 (TNSrep) -- Gartner, an information technology research and advisory company, issued the following news release:* * *
Gartner Predicts by 2027, 50% of Enterprises Without a People Centric AI Strategy Will Lose Their Top AI Talent
Organizations Must Address Four Workforce Dynamics to Achieve AI Results
*
By 2027, half of enterprises lacking a comprehensive AI people strategy will lose their top AI talent to competitors who prioritize workforce enablement over basic adoption, according to Gartner, Inc., a business and technology insights company.
The Gartner Global ... Show Full Article STAMFORD, Connecticut, May 16 (TNSrep) -- Gartner, an information technology research and advisory company, issued the following news release: * * * Gartner Predicts by 2027, 50% of Enterprises Without a People Centric AI Strategy Will Lose Their Top AI Talent Organizations Must Address Four Workforce Dynamics to Achieve AI Results * By 2027, half of enterprises lacking a comprehensive AI people strategy will lose their top AI talent to competitors who prioritize workforce enablement over basic adoption, according to Gartner, Inc., a business and technology insights company. The Gartner GlobalLabor Market Survey, conducted in 1Q26, surveyed 12,004 employees and managers across 40 countries, providing benchmarks on AI's impact on work, worker sentiment and workforce enablement.
"The survey revealed that in the shift to an AI-powered workforce, most leaders are mistaking basic access or adoption metrics for transformation," said Swagatam Basu, Senior Director Analyst, in the Gartner HR practice. "This 'enablement illusion' is hiding risks and draining ROI."
Many leaders also lack strategic preparedness: A December 2025 Gartner survey of 197 CxOs and senior business leaders revealed that only 27% of executives have a comprehensive AI strategy, and just 20% believe their workforce is truly AI-ready.
Gartner has identified four workforce dynamics that organizations must address to achieve AI results:
Measuring AI Impact by Time Saved Misses the Real Value
Many executives are tracking AI success by hours saved, yet 19% of employees surveyed by Gartner in 1Q26 reported no time saved with AI. Organizations instead must focus on effective and diverse AI use: Employees who are proficient with AI across multiple use cases are twice as likely to be highly productive, 2.3 times more likely to deliver high-quality work and 3.2 times more likely to drive effective process improvements (see Figure 1).
Figure 1: AI Productivity Is Not Linear -- It Is a Threshold
Leaders should move beyond tracking basic adoption and implement a "True ROI Index" focused on the depth and diversity of AI use. A central repository for AI use cases enables organizations to capture lessons learned and organizational knowledge while minimizing duplication and accelerating enterprisewide learning and productivity gains.
Many Employees Prefer Personal AI Over Company Tools
"Eighty-eight percent of employees with enterprise AI access also use personal AI tools for business tasks, often to save time," said Diana Sanchez, Senior Director Analyst, in the Gartner HR practice. "While hybrid AI users are 1.7 times more likely to report significant time saved over those using only enterprise solutions, this behavior increases corporate data risk and also drives attrition risks with critical talent."
CIOs and CHROs must partner to audit and improve the user experience of enterprise AI tools to reduce shadow AI, protect data and retain talent. In parallel, CHROs should clarify AI governance and decision rights, ensuring HR is represented in governance bodies to proactively manage people-related risks and workforce impacts.
Major AI Promises Are Not Reaching Most Employees
Although most employees are offered enterprise AI, 73% of highly productive users are managers or executives. Individual contributors - those responsible for the majority of automatable tasks - are often underserved with support and guidance.
Without support and guidance for individual contributors, AI's benefits remain concentrated at the top, limiting enterprisewide productivity and impact boosts.
To bridge the utilization gap separating individual contributors from leadership, CHROs should provide targeted tools and training to build managerial confidence and capability. Managers are best positioned to integrate AI into daily workflows, provide context on how to work alongside AI tools, and encourage experimentation and creativity.
Absence of Psychological Safety Is Slowing AI Adoption
Widespread anxiety about AI-driven job loss is undermining productivity and slowing adoption throughout the workforce. AI adoption is a culture issue, not just a training issue; standard software training and technical learning do not improve workforce sentiment or build trust.
"Employees with a positive outlook toward AI are 3.4 times more likely to be highly productive," said Basu. "The most effective drivers of positive AI adoption are employee confidence in their current and future roles, and transparent, ongoing communication about how AI will be used and its impact on jobs."
Leaders need to provide clear communication about how jobs and skills will evolve with AI and set clear human-AI collaboration norms to reduce anxiety about job preparedness. Regular trust pulse surveys should include monitoring workforce sentiment around AI and leaders must address concerns early and proactively.
Gartner clients can read more in the report: AI-Workplace Outlook for 1Q26: Benchmarks and Trends on AI, Work, and the Workforce (https://www.gartner.com/document-reader/document/code/854317).
* * *
Gartner is the World Authority on AI
Gartner is an indispensable partner to C-Level executives and technology providers as they implement AI strategies to achieve their mission-critical priorities. The independence and objectivity of Gartner insights provide clients with the confidence to make informed decisions and unlock the full potential of AI. Clients across the C-Level are using Gartner's proprietary Ask Gartner AI tool to determine how to leverage AI in their business. With more than 2,500 business and technology experts, 6,000 written insights, as well as more than 4,000 AI use cases and case studies, Gartner is the world authority on AI. More information can be found here.
* * *
About the Gartner HR Symposium/Xpo
Gartner HR Symposium/Xpo is where CHROs and their leadership teams gather each year to reimagine their strategies through the lens of Gartner's research-driven insights and expert advice on leadership and learning, employee experience, culture and change, talent acquisition and workforce planning, and HR technology. Gartner HR Symposium/Xpo will be held October 6-8 in London, October 26-28 in Florida, and November 16-17 in Sydney. Follow news and updates from these events on LinkedIn using #GartnerHR.
* * *
About Gartner for HR Leaders
The Gartner HR practice brings together the best relevant content approaches across Gartner to offer individual decision makers strategic business advice on the mission-critical priorities that cut across the HR function. Additional information is available at https://www.gartner.com/en/human-resources/products/gartner-for-hr. Follow news and updates from the Gartner HR practice on X and LinkedIn using #GartnerHR.
* * *
Original text here: https://www.gartner.com/en/newsroom/press-releases/2026-05-13-gartner-predicts-by-2027-50-percent-of-enterprises-without-a-people-centric-ai-strategy-will-lose-their-top-ai-talent
[Category: BizConsulting]
BAE Systems Delivers Next-Generation Flight Hardware for U.S. Space Force Missile Warning Program
ARLINGTON, Virginia, May 16 -- BAE Systems issued the following news release:* * *
BAE Systems delivers next-generation flight hardware for U.S. Space Force missile warning program
Sensor system delivered for full assembly of U.S. Space Force satellite intelligence and defense payload
*
BAE Systems has delivered the sensor subassembly and sensor system controller components for the Next Generation Overhead Persistent Infrared Polar (NGP) program. The program will provide the U.S. Space Force with advanced missile warning, technical intelligence and battlespace characterization mission capabilities.
This ... Show Full Article ARLINGTON, Virginia, May 16 -- BAE Systems issued the following news release: * * * BAE Systems delivers next-generation flight hardware for U.S. Space Force missile warning program Sensor system delivered for full assembly of U.S. Space Force satellite intelligence and defense payload * BAE Systems has delivered the sensor subassembly and sensor system controller components for the Next Generation Overhead Persistent Infrared Polar (NGP) program. The program will provide the U.S. Space Force with advanced missile warning, technical intelligence and battlespace characterization mission capabilities. Thismilestone delivery keeps the program on track for full assembly of the payload, known as Flight Unit 1, expected to launch in 2028.
"We met multiple challenges across a multiyear timeframe to successfully deliver our components for the next stage of full payload assembly," said Thai Sheridan, vice president and general manager of Military Space for BAE Systems Space & Mission Systems. "This program will provide essential next-generation defense and intelligence capabilities for the Space Force."
The sensor subassembly built by BAE Systems is a significant component of the mission payload and provides the optics, pointing mechanism, controlling electronics and electrical bus interface to the spacecraft.
The sensor system controller interfaces directly to the space vehicle to receive commands and provide telemetry data for the mission. It provides power control and conversion for sensor assembly components as well as high-accuracy mirror direction.
The BAE Systems hardware originally was designed for use with the geosynchronous Earth orbit (GEO) element of the program. Featuring a highly adaptable design, the components were able to be repurposed for the NGP mission, allowing the program to meet challenging schedule needs.
BAE Systems is building a second flight unit for the NGP mission, which is on schedule for delivery in support of an expected launch in 2030.
* * *
Original text here: https://www.baesystems.com/en/article/bae-systems-delivers-next-generation-flight-hardware-for-us-space-force-missile-warning-program
[Category: BizNational Defense]
Akamai Technologies Announces Intent to Acquire LayerX, Advancing Its Workforce Security Strategy With AI Usage Control
CAMBRIDGE, Massachusetts, May 16 -- Akamai Technologies, a provider of content delivery network services, issued the following news release on May 14, 2026:* * *
Akamai Technologies Announces Intent to Acquire LayerX, Advancing Its Workforce Security Strategy with AI Usage Control
Uniting browser-native controls with Akamai's Zero Trust and application security portfolio to secure the AI-era workforce
*
Akamai Technologies, Inc. (NASDAQ: AKAM), announces that it has entered into a definitive agreement to acquire LayerX, a leading provider of browser-based AI usage control and secure enterprise ... Show Full Article CAMBRIDGE, Massachusetts, May 16 -- Akamai Technologies, a provider of content delivery network services, issued the following news release on May 14, 2026: * * * Akamai Technologies Announces Intent to Acquire LayerX, Advancing Its Workforce Security Strategy with AI Usage Control Uniting browser-native controls with Akamai's Zero Trust and application security portfolio to secure the AI-era workforce * Akamai Technologies, Inc. (NASDAQ: AKAM), announces that it has entered into a definitive agreement to acquire LayerX, a leading provider of browser-based AI usage control and secure enterprisebrowser (SEB) technology. LayerX's solutions will extend Akamai's protection into the browser, where the majority of enterprise tasks now occur and where today's workforce engages with generative AI applications, SaaS AI solutions, and AI agents. With this acquisition, Akamai is taking a critical step in the evolution of its Zero Trust security portfolio and addressing one of the most urgent priorities for security leaders in 2026: AI usage control.
LayerX supports the most popular browsers, unlike proprietary enterprise browsers that require organizations to switch browsers and disrupt their users. This allows the users to securely continue with their preferred browser without disruption, as well as leverage the new generation of agentic browsers including Atlas, Comet, and others. By accommodating existing browsers, security teams benefit from greater real-time visibility and control over uninhibited use, including when users interact with web content, prompts, file uploads, and SaaS applications. LayerX enables this without infrastructure changes or creating new workforce friction.
"Our customers are adopting AI at record speed, and they're telling us the same thing: Their existing controls cannot see how employees are interacting with AI tools and sharing with large language models," said Mani Sundaram, Executive Vice President and General Manager, Security Technology Group, Akamai. "The acquisition of LayerX helps close that gap, providing Akamai with a control layer that governs AI at the point of use so enterprises can move at AI speed without compromising safety and compliance."
Combined with Akamai's existing Zero Trust portfolio capabilities, which include Zero Trust Network Access (ZTNA), runtime protection of AI applications, and workload-level segmentation of AI inference, Akamai is delivering AI usage control that spans the user, the application, and the infrastructure. Together, these deliver the high-performance, scalable security that customers around the world have relied on for nearly three decades.
"Securing human and agentic AI usage has become one of the defining challenges in enterprise security," said Or Eshed, Chief Executive Officer and Co-Founder, LayerX. "We're giving enterprises the foundation to deploy AI safely at a global scale by bringing LayerX's technology together with Akamai's Zero Trust portfolio and the world's most distributed edge platform. We are thrilled to have the opportunity to accelerate our security vision through this deal."
LayerX employees, including Co-Founders Or Eshed and David Vaisbrud, will join Akamai's Zero Trust organization. As Akamai's fourth Tel Aviv-based cybersecurity acquisition in the past five years, LayerX will further the technical depth and expertise of its growing cybersecurity innovation hub in the region.
Under terms of the agreement, Akamai has agreed to acquire all of the outstanding equity of LayerX for approximately US$205 million, after giving effect to expected purchase price adjustments. The closing of the transaction, which is subject to customary closing conditions, is expected to occur in the third quarter of 2026. The acquisition is anticipated to be dilutive to Akamai's non-GAAP EPS by approximately US$0.12 for fiscal year 2026, and the LayerX business is expected to have annual recurring revenue at year end of approximately US$10 million.
* * *
About Akamai
Akamai is the cybersecurity and cloud computing company that powers and protects business online. Our market-leading security solutions, superior threat intelligence, and global operations team provide defense in depth to safeguard enterprise data and applications everywhere. Akamai's full-stack cloud computing solutions deliver performance and affordability on the world's most distributed platform. Global enterprises trust Akamai to provide the industry-leading reliability, scale, and expertise they need to grow their business with confidence.
* * *
Akamai Statement Under the Private Securities Litigation Reform Act
This press release contains statements that are not statements of historical fact and constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about potential synergies and other benefits of the transaction to Akamai. Each of the forward-looking statements is subject to change as a result of various important factors, many of which are beyond Akamai's control, including, but not limited to: Akamai's inability to achieve the expected benefits of the transaction; challenges integrating LayerX's business, employees, and technology; and effects of competition. The forward-looking statements contained herein are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Akamai disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
* * *
Original text: https://www.akamai.com/newsroom/press-release/akamai-technologies-announces-intent-to-acquire-layerx-advancing-its-workforce-security-strategy-with-ai-usage-control
[Category BizComputer Technology]
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of Nubeqa Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer
WHIPPANY, New Jersey, May 16 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news:* * *
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA(R) (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
* Primary results from the Phase II ARASEC trial show that NUBEQA(R) (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with metastatic ... Show Full Article WHIPPANY, New Jersey, May 16 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news: * * * AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA(R) (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer * Primary results from the Phase II ARASEC trial show that NUBEQA(R) (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with metastaticcastration-sensitive prostate cancer (mCSPC) compared to a matched ADT-alone arm from a historical control in the CHAARTED trial
* ARASEC is a multicenter, open-label trial in U.S. patients designed to be complementary to the pivotal Phase III ARANOTE trial
* Results are being presented today as a plenary session during the American Urological Association (AUA) Annual Meeting
*
New data from the Phase II ARASEC trial show NUBEQA(R) (darolutamide) plus androgen deprivation therapy (ADT) resulted in a 71% reduction in the risk of progression or death per CHAARTED criteria compared to ADT alone (HR 0.29; 95% CI 0.20-0.40; P<0.001) in U.S. patients (N=320) with metastatic castration-sensitive prostate cancer (mCSPC). NUBEQA plus ADT was also associated with significant improvements in overall survival (OS) (HR 0.50; 95% CI 0.30-0.82; P=0.003), time to metastatic castration-resistant prostate cancer (mCRPC) (HR 0.26; 95% CI 0.18-0.38; P<0.001), and radiological progression-free survival (rPFS) (HR 0.30; 95% CI 0.19-0.48; P<0.001) vs a matched ADT alone arm from a historical control./1
Some notable limitations of the study include: open-label Phase II study design, the absence of randomization, and the use of historical external control. Primary results are being presented today as a plenary session during the American Urological Association (AUA) Annual Meeting.
NUBEQA is indicated in the U.S. for the treatment of adult patients with mCSPC, both with and without docetaxel, and for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC)./2
In the ARASEC trial, no new safety signals were observed in the NUBEQA plus ADT arm, consistent with previous studies. Safety results were reported descriptively for the NUBEQA plus ADT arm only, as safety data were not routinely collected in the CHAARTED ADT-alone arm. In the NUBEQA plus ADT matched population, 58% of treatment-emergent adverse events (TEAEs) were grade 1/2 and 8% discontinued NUBEQA due to TEAEs.
* * *
"Results from the Phase II ARASEC trial provide additional evidence regarding the efficacy and safety of darolutamide plus ADT in patients with mCSPC. The data further support NUBEQA's ability to offer physicians and patients with prostate cancer a treatment option that is both effective and generally well tolerated."
- Rana R. McKay, MD , Medical Oncologist and Professor of Medicine, Urology, and Radiation Medicine and Applied Sciences and Principal Investigator of the ARASEC trial
* * *
Prostate cancer is the leading cancer diagnosis among men in the U.S.3 Around 313,780 men are diagnosed with prostate cancer each year and about 35,770 die from the disease in the U.S./3 By 2040, prostate cancer diagnoses are projected to increase to 2.9 million worldwide./4 For men with mCSPC, just over a third (~38%) will survive five years or more after diagnosis,/5 and most progress to castration-resistant prostate cancer (CRPC), a condition with limited long-term survival./6,7
"The ARASEC trial was designed to further evaluate NUBEQA plus ADT in patients with metastatic castration-sensitive prostate cancer using a rigorous and innovative study approach," said Yesmean Wahdan, Senior Vice President and Head of Medical Affairs, U.S. and North America Pharmaceuticals at Bayer. "Supported by our robust clinical development program, these results add to the growing body of evidence demonstrating the efficacy and tolerability of NUBEQA and reinforce our commitment to expanding treatment options for patients earlier in the disease."
* * *
About the ARASEC trial/8
ARASEC (NCT05059236), is a U.S. prospective open-label, multicenter, Phase II study with an external control arm, complementary to the ARANOTE trial. The study compares NUBEQA plus ADT with a historical external ADT-alone control arm. Patients with mCSPC on conventional imaging and no prior systemic therapy were prospectively enrolled to receive NUBEQA 600 mg twice daily plus ADT. Patients were matched 1:1 to patients enrolled on the ADT-alone arm of the Phase III CHAARTED study using propensity scores based on baseline prognostic characteristics (age, ECOG performance status, CHAARTED-defined extent of disease, prior local therapy, Gleason score, baseline prostate-specific antigen [PSA]). The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), time to metastatic castration-resistant prostate cancer (mCRPC), radiological PFS (rPFS; based on imaging frequency as clinically indicated), PSA <0.2 ng/mL response rates, and safety (reported descriptively for the darolutamide plus ADT arm only, as safety data were not routinely collected in the CHAARTED ADT-alone arm).
Potential limitations of the study include: open-label Phase II study design, the absence of randomization, and the use of historical external control. Although propensity score matching was used, this method only adjusts for measured variables; unknown or unmeasured confounders may still remain. Use of a historical external control arm may introduce bias due to changes in standards of care over time, differences in endpoint definitions, and assessment methods.
* * *
About NUBEQA(R) (darolutamide)/2
NUBEQA(R) (darolutamide) is an androgen receptor inhibitor (ARi) with a distinct chemical structure that competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription.
NUBEQA was developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with:
* Non-metastatic castration-resistant prostate cancer (nmCRPC)
* Metastatic castration-sensitive prostate cancer (mCSPC)
* Metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel
IMPORTANT SAFETY INFORMATION
Warnings & Precautions
Ischemic Heart Disease - Ischemic heart disease, including fatal cases, occurred in patients receiving NUBEQA.
In a pooled analysis of ARAMIS and ARANOTE, ischemic heart disease occurred in 3.4% of patients receiving NUBEQA and 2.2% receiving placebo, including Grade 3-4 events in 1.4% and 0.3%, respectively. Ischemic events led to death in 0.4% of patients receiving NUBEQA and 0.4% receiving placebo.
In ARASENS, ischemic heart disease occurred in 3.2% of patients receiving NUBEQA with docetaxel and 2% receiving placebo with docetaxel, including Grade 3-4 events in 1.3% and 1.1%, respectively. Ischemic events led to death in 0.3% of patients receiving NUBEQA with docetaxel and 0% receiving placebo with docetaxel.
Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue NUBEQA for Grade 3-4 ischemic heart disease.
Seizure - Seizure occurred in patients receiving NUBEQA.
In a pooled analysis of ARAMIS and ARANOTE, Grade 1-3 seizure occurred in 0.2% of patients receiving NUBEQA. Seizure occurred from 261 to 665 days after initiation of NUBEQA.
In ARASENS, seizure occurred in 0.8% of patients receiving NUBEQA with docetaxel, including two Grade 3 events. Seizure occurred from 38 to 1754 days after initiation of NUBEQA.
It is unknown whether anti-epileptic medications will prevent seizures with NUBEQA. Advise patients of the risk of developing a seizure while receiving NUBEQA and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others. Consider discontinuation of NUBEQA in patients who develop a seizure during treatment.
Embryo-Fetal Toxicity - The safety and efficacy of NUBEQA have not been established in females. NUBEQA can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception during treatment with NUBEQA and for 1 week after the last dose.
Adverse Reactions
In ARAMIS, serious adverse reactions occurred in 25% of patients receiving NUBEQA and in 20% of patients receiving placebo. Serious adverse reactions in 1% of patients who received NUBEQA included urinary retention, pneumonia, and hematuria. Fatal adverse reactions occurred in 3.9% of patients receiving NUBEQA and 3.2% of patients receiving placebo. Fatal adverse reactions that occurred in 2 patients who received NUBEQA included death (0.4%), cardiac failure (0.3%), cardiac arrest (0.2%), general physical health deterioration (0.2%), and pulmonary embolism (0.2%). The most common (>2% with a 2% increase compared to placebo) adverse reactions, including laboratory test abnormalities, were increased AST (23%), decreased neutrophil count (20%), fatigue (16%), increased bilirubin (16%), pain in extremity (6%), and rash (4%). Clinically relevant adverse reactions occurring in 2% or more of patients treated with NUBEQA included ischemic heart disease (4%) and heart failure (2.1%).
In ARANOTE, serious adverse reactions occurred in 24% of patients receiving NUBEQA. Serious adverse reactions in 1% of patients who received NUBEQA included pneumonia (2%), urinary tract infection (1.8%), musculoskeletal pain (1.6%), hemorrhage (1.6%), arrhythmias (1.3%), and spinal cord compression (1.1%). Fatal adverse reactions occurred in 4.7% of patients receiving NUBEQA and those that occurred in 2 patients included sepsis (1.1%), craniocerebral injury (0.4%), and myocardial infarction (0.4%). The most common (10% with a 2% increase compared to placebo) adverse reaction is urinary tract infection (12%). The most common laboratory test abnormalities (15% with a 5% increase over placebo) are increased AST (32%), increased ALT (28%), increased bilirubin (17%), and decreased neutrophil count (16%). Clinically relevant adverse reactions in <10% of patients who received NUBEQA included arrhythmia (8.8%), pneumonia (3.6%), and myocardial infarction (0.7%).
In ARASENS, serious adverse reactions occurred in 45% of patients receiving NUBEQA with docetaxel. Serious adverse reactions in 2% of patients who received NUBEQA with docetaxel included febrile neutropenia (6%), neutrophil count decreased (2.8%), musculoskeletal pain (2.6%) and pneumonia (2.6%). Fatal adverse reactions occurred in 4% of patients receiving NUBEQA with docetaxel. Fatal adverse reactions in 2 patients who received NUBEQA included COVID-19/COVID-19 pneumonia (0.8%), myocardial infarction (0.3%), and sudden death (0.3%). The most common (10% with a 2% increase over placebo with docetaxel) adverse reactions are constipation (23%), rash (20%), decreased appetite (19%), hemorrhage (18%), increased weight (18%), and hypertension (14%). The most common laboratory test abnormalities (30%) are anemia (72%), hyperglycemia (57%), decreased lymphocyte count (52%), decreased neutrophil count (49%), increased AST (40%), increased ALT (37%), and hypocalcemia (31%). Clinically relevant adverse reactions in <10% of patients who received NUBEQA with docetaxel included fractures (8%), ischemic heart disease (3.2%), seizures (0.6%), and drug-induced liver injury (0.3%).
Drug Interactions
Effect of Other Drugs on NUBEQA - Concomitant use of NUBEQA with a combined P-gp and strong or moderate CYP3A4 inducer decreases darolutamide exposure which may decrease NUBEQA activity. Avoid concomitant use of NUBEQA with combined P-gp and strong or moderate CYP3A4 inducers.
Concomitant use of NUBEQA with a combined P-gp and strong CYP3A4 inhibitor increases darolutamide exposure which may increase the risk of NUBEQA adverse reactions. Monitor patients more frequently for NUBEQA adverse reactions and modify NUBEQA dosage as needed.
Effects of NUBEQA on Other Drugs - NUBEQA is an inhibitor of BCRP transporter. Concomitant use of NUBEQA increases the AUC and Cmax of BCRP substrates, which may increase the risk of BCRP substrate-related toxicities. Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions, and consider dose reduction of the BCRP substrate drug.
NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters. Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates. Monitor patients more frequently for adverse reactions of these drugs and consider dose reduction while patients are taking NUBEQA.
Review the Prescribing Information of drugs that are BCRP, OATP1B1, and OATP1B3 substrates when used concomitantly with NUBEQA.
For important risk and use information about NUBEQA, please see the accompanying full Prescribing Information.
* * *
About Metastatic Castration-Sensitive Prostate Cancer
Prostate cancer is the leading cancer diagnosis among men in the U.S.3 Around 313,780 men are diagnosed with prostate cancer each year and about 35,770 die from the disease in the U.S.3
At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. mCSPC is an advanced form of prostate cancer, when the cancer has spread beyond the prostate to other organs but is still responding to hormone therapy that lowers testosterone, such as androgen deprivation therapy (ADT). Despite treatment, most men with mCSPC will eventually progress to castration-resistant prostate cancer, a condition with limited survival.6,7
* * *
About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer includes six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
* * *
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros.
* * *
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
* * *
References
1/ McKay R, et al. Darolutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive
prostate cancer (mHSPC): ARASEC - US prospective, open-label phase 2 study with an external control arm. The Journal of Urology. May 14, 2026. https://doi.org/10.1097/01.JU.0001192572.07890.f8. Presented at AUA 2026.
2/ NUBEQA(R) (darolutamide) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; June 2025..
3/ National Cancer Institute. Cancer Stat Facts: Common Cancer Sites. https://seer.cancer.gov/statfacts/html/common.html. Accessed January 2026.
4/ James ND, et al. Lancet 2024; 403: 1683-722.
5/ National Cancer Institute. Cancer Stat Facts: Prostate Cancer. https://seer.cancer.gov/statfacts/html/prost.html. Accessed January 2026.
6/ Siegel DA, et al. MMWR Morb Mortal Wkly Rep 2020; 69:1473-1480.
7/ Hahn A, et al. Am Soc Clin Oncol Educ Book. 2018; 23;38:363-371.
8/ ClinicalTrials.gov NCT05059236. A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (ARASEC). https://clinicaltrials.gov/study/NCT05059236. Accessed January 2026.
* * *
Original text here: https://www.bayer.com/en/us/news-stories/arasec-data
[Category: BizPharmaceuticals]